Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1254 daily bars · split adjusted
Current price $0.0002
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Nov 6, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 20, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jan 26, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 16, 22 | Maxim Group | downgrade | Buy | Hold |
| Jul 20, 21 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 15, 20 | H.C. Wainwright | maintain | Buy | Buy |
| May 15, 20 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Feb 19, 20 | Roth Capital | maintain | Buy | Buy |
| Dec 30, 19 | H.C. Wainwright | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 91.60 | Oscillator | Sell |
| Stochastic %K (14, 3, 3) | 33.33 | Oscillator | Neutral |
| Williams %R (14) | 0.00 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.00 (Hist 0.00) | Oscillator | Strong Buy |
| Average Directional Index (14) | 9.94 (+DI 90.2 / -DI 7.6) | Trend | Neutral |
| EMA 20 | 0.00 | MA | Strong Buy |
| SMA 20 | 0.00 | MA | Strong Buy |
| EMA 50 | 0.00 | MA | Strong Buy |
| SMA 50 | 0.00 | MA | Strong Buy |
| SMA 200 | 0.00 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | ARDS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.0x | -1.4x · sector 20.7x | Discount |
| Forward P/E (FY23E) | 0.0x | EPS est. 0.07 | Discount |
| Price / Book | -0.0x | 0.4x | Discount |
| Price / Sales | — | 21.0x | Discount |
| EV / EBITDA | -0.0x | -0.9x | Discount |
| Return on equity | 164.7% | — | Top tier |
| Gross margin | 0.0% | 60.0% | Below hist. |
| Debt / Equity | -0.25 | -0.16 | Conservative |
| Piotroski / Altman Z | 4/9 | Z -40.63 | Distress |
Discounted cash flow model
Stock news · updated daily
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced he
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
Reported EPS vs. consensus estimate
FY2019 · 10-K disclosure
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 27, 24 | Windham-Bannister Susan Richards | director | A-Award | 200,000 @ $0.063 | $12.60K |
| Jun 27, 24 | Hamilton John F | director | A-Award | 200,000 @ $0.063 | $12.60K |
| Jun 27, 24 | Jafri Hasan | officer: Chief Medical Officer | A-Award | 250,000 @ $0.063 | $15.75K |
| Jun 24, 24 | Patzer Eric | director | P-Purchase | 714,286 @ $0.07 | $50.00K |
| Jun 24, 24 | Truong Vu | director, officer: CEO | P-Purchase | 714,286 @ $0.07 | $50.00K |
| Sep 18, 23 | Hamilton John F | director | A-Award | 15,000 @ $0.08 | $1.20K |
| Sep 18, 23 | Windham-Bannister Susan Richards | director | A-Award | 15,000 @ $0.08 | $1.20K |
| Sep 18, 23 | Patzer Eric | director, officer: Executive Chairman | A-Award | 15,000 @ $0.08 | $1.20K |